Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.

Leukemia research - 1 Jan 2008

Ng Heng Joo, Tan Daryl C L, Yiu Richard C, How Gee Fung

Abstract excerpt

Patients with primary hypereosinophilic disorders who are positive for the FIP1L1-PDGFRA fusion gene mutation are highly responsive to therapy with imatinib mesylate. A 35-year-old man with FIP1L1-PDGFRA positive hypereosinophilic syndrome and cardiac involvement, was treated with imatinib 100 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Hypereosinophilic Syndrome
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to mRNA Cleavage and Polyadenylation Factors

Share to Oncogene Proteins, Fusion

Share to Piperazines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Remission Induction

Source

Identifiers

PMID: 17544504
DOI: 10.1016/j.leukres.2007.04.004

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17544504-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.PMID 17544504Read ↗

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Semantic proximity Read ↗

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.Semantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeSemantic proximity Read ↗

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcriptSemantic proximity Read ↗

The FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaSemantic proximity Read ↗

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.Semantic proximity Read ↗

Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.